IPP Bureau
Lupin receives USFDA approval for Brivaracetam Tablets
By IPP Bureau - December 23, 2022
Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets
By IPP Bureau - December 23, 2022
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
Alembic Pharmaceuticals receives PAS approval from USFDA for Pregabalin capsules
By IPP Bureau - December 23, 2022
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
Strides Pharma Global receives AUD 94 mn for sale of Australia's operations
By IPP Bureau - December 23, 2022
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
PM emphasises need for strengthened surveillance with focus on genome sequencing and increased testing
By IPP Bureau - December 23, 2022
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
Lupin Diagnostics expands footprint in Central India
By IPP Bureau - December 22, 2022
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes
By IPP Bureau - December 22, 2022
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Vaishali Pharma signs partnership agreement with Jark Pharma
By IPP Bureau - December 22, 2022
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
By IPP Bureau - December 22, 2022
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Supriya Lifescience signs solar agreement with Enrich Energy
By IPP Bureau - December 22, 2022
The project will generate and supply green energy to fulfill about 50% present consumption of the company
Torrent board approves Scheme of Amalgamation of Curatio Health Care
By IPP Bureau - December 22, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer
By IPP Bureau - December 22, 2022
He has published more than 100 research papers in several prestigious national and international journals
WBF signs MOU with Sharda University to help advance biocontrol sector
By IPP Bureau - December 21, 2022
Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
By IPP Bureau - December 21, 2022
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
